Eli Lilly vs Novo Nordisk

Eli Lilly and Novo Nordisk are two pharmaceutical giants that are prominent players in the healthcare sector. Both companies have a strong track record of developing innovative drugs and treatments for various medical conditions. Investors often compare and contrast the stocks of Eli Lilly and Novo Nordisk, considering factors such as financial performance, product pipelines, and market presence. Understanding the strengths and weaknesses of these companies can help investors make informed decisions about where to allocate their capital in the ever-evolving pharmaceutical industry.

Eli Lilly or Novo Nordisk?

When comparing Eli Lilly and Novo Nordisk, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Eli Lilly and Novo Nordisk.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Eli Lilly has a dividend yield of 0.55%, while Novo Nordisk has a dividend yield of 1.23%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Eli Lilly reports a 5-year dividend growth of 14.97% year and a payout ratio of 59.60%. On the other hand, Novo Nordisk reports a 5-year dividend growth of 10.60% year and a payout ratio of 46.71%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Eli Lilly P/E ratio at 112.07 and Novo Nordisk's P/E ratio at 40.05. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Eli Lilly P/B ratio is 60.67 while Novo Nordisk's P/B ratio is 31.99.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Eli Lilly has seen a 5-year revenue growth of 0.81%, while Novo Nordisk's is 1.24%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Eli Lilly's ROE at 60.72% and Novo Nordisk's ROE at 87.50%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $907.80 for Eli Lilly and $117.14 for Novo Nordisk. Over the past year, Eli Lilly's prices ranged from $547.61 to $972.53, with a yearly change of 77.60%. Novo Nordisk's prices fluctuated between $92.94 and $148.15, with a yearly change of 59.40%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.